CD20 Antibody (CL10613) - BSA Free

Name: CD20 Antibody (CL10613) - BSA Free
Brand: Novus Biologicals
SKU: NBP3-07979
Price: 429 USD
Availability: InStock

Novus Biologicals | Catalog # NBP3-07979

Submit a review

Product Documents

View Available Conjugates View Available Formulations

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas
Related Blogs

Key Product Details

Validated by

Orthogonal Validation

Species Reactivity

Human

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG_2A Clone # CL10613

Format

BSA Free

View all CD20 Primary Antibodies »

Product Specifications

Immunogen

This antibody was developed using a recombinant protein derived from P11836, with the exact immunogen sequence remaining proprietary.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG_2A

Description

Novus Biologicals Mouse CD20 Antibody (CL10613) - BSA Free (NBP3-07979) is a monoclonal antibody validated for use in IHC and WB. All Novus Biologicals antibodies are covered by our 100% guarantee.

Scientific Data Images for CD20 Antibody (CL10613) - BSA Free

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979]

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979] - Analysis in human lymph node and cerebral cortex tissues using NBP3-07979 antibody. Corresponding CD20 RNA-seq data are presented for the same tissues.

Western Blot: CD20 Antibody (CL10613) [NBP3-07979]

Western Blot: CD20 Antibody (CL10613) [NBP3-07979] - Analysis in human cell line Daudi.

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979]

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979] - Staining of human lymph node shows strong membranous positivity in germinal center cells.

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979]

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979] - Staining of human cerebral cortex shows no positivity in neurons as expected.

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979]

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979] - Staining of human colon shows strong membranous positivity in a small subset of lymphoid cells.

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979]

Immunohistochemistry-Paraffin: CD20 Antibody (CL10613) [NBP3-07979] - Staining of human liver shows no positivity in hepatocytes as expected.

View 3 more images

Applications for CD20 Antibody (CL10613) - BSA Free

Application

Recommended Usage

Immunohistochemistry

1:500 - 1:1000

Immunohistochemistry-Paraffin

1:500 - 1:1000

Western Blot

1 ug/ml

Application Notes

For IHC-Paraffin, HIER pH 6 retrieval is recommended.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.2) and 40% Glycerol

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CD20

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Long Name

Cluster of Differentiation 20

Alternate Names

B1, Bp35, CD20, LEU-16, Ly-44, MS4A1, S7

Gene Symbol

MS4A1

Additional CD20 Products

Product Documents for CD20 Antibody (CL10613) - BSA Free

Download Product Datasheets

Download SDS

Product Specific Notices for CD20 Antibody (CL10613) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.